Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-Year Randomised Double-Blind Placebo-Controlled International Multicentre Study

Trial Profile

Effects of Ivabradine on Cardiovascular Events in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction. A Three-Year Randomised Double-Blind Placebo-Controlled International Multicentre Study

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Left ventricular dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms BEAUTIFUL
  • Most Recent Events

    • 28 Oct 2009 Results of new sub-analyses were presented today at the 2009 Canadian Cardiovascular Congress, according to a Montreal Heart Institute media release.
    • 31 Aug 2009 Subgroup results presented at ESC 2009, as reported in a Servier media release.
    • 31 Aug 2008 Results presented at ESC 2008 and published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top